logo

Blueprint Medicines (BPMC)



Trade BPMC now with
  Date
  Headline
8/7/2019 8:17:17 AM Blueprint Medicines Says FDA Accepts NDA For Avapritinib For PDGFRA Exon 18 Mutant GIST And Fourth-Line GIST
8/1/2019 7:08:37 AM Blueprint Medicines Q2 Net Loss $99.7 Mln Vs. Net Loss $27 Mln Last Year
6/15/2019 6:03:48 AM Blueprint Medicines Presents Updated EXPLORER Trial Data For Avapritinib In Patients With Systemic Mastocytosis
6/14/2019 8:48:43 AM Blueprint Medicines Submits New Drug Application To FDA For Avapritinib
5/9/2019 7:14:21 AM Blueprint Medicines Q1 Net Loss Widens To $87.4 Mln Or $1.98/shr From $56.5 Mln Or $1.29/shr Last Year
4/2/2019 4:01:48 PM Blueprint Medicines Announces Closing Of Public Offering
3/27/2019 4:09:41 PM Blueprint Medicines Announces Proposed Public Offering Of Shares Of Common Stock
2/26/2019 7:13:55 AM Blueprint Medicines Q4 Net Loss $80.3 Mln Or $1.83/Shr Vs Loss Of $49.0 Mln Or $1.23/Shr Last Year
1/7/2019 7:35:55 AM Wedbush Reiterates Blueprint Medicines (BPMC) At Outperform With $103 Price Target
11/16/2018 6:27:22 AM Wedbush Reiterates Blueprint Medicines (BPMC) At Outperform With $103 Price Target
10/30/2018 7:22:17 AM Blueprint Medicines Q3 Net Loss $72.7 Mln Or $1.66/Shr Vs Loss $37.7 Mln Or $0.96/Shr Last Year
10/22/2018 7:09:50 AM Wedbush Reiterates Blueprint Medicines (BPMC) At Outperform With $101 Price Target
10/8/2018 6:38:40 AM Wedbush Reiterates Blueprint Medicines (BPMC) At Outperform With $101 Price Target
10/6/2018 9:21:41 AM Blueprint Medicines Reports Presentation Of Updated Data From Ongoing Phase 1 ARROW Clinical Trial Of BLU-667
10/1/2018 8:22:27 AM Blueprint Medicines Presents Foundational Preclinical Data Supporting The Development Of BLU-782 For FOP
  
 
>